These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989 [TBL] [Abstract][Full Text] [Related]
5. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. Hume SP; Luthra SK; Brown DJ; Opacka-Juffry J; Osman S; Ashworth S; Myers R; Brady F; Carroll FI; Kuhar MJ; Brooks DJ Nucl Med Biol; 1996 Apr; 23(3):377-84. PubMed ID: 8782251 [TBL] [Abstract][Full Text] [Related]
7. Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. Fowler JS; Volkow ND; Logan J; Gatley SJ; Pappas N; King P; Ding YS; Wang GJ Synapse; 1998 Feb; 28(2):111-6. PubMed ID: 9450511 [TBL] [Abstract][Full Text] [Related]
8. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. Villemagne V; Yuan J; Wong DF; Dannals RF; Hatzidimitriou G; Mathews WB; Ravert HT; Musachio J; McCann UD; Ricaurte GA J Neurosci; 1998 Jan; 18(1):419-27. PubMed ID: 9412518 [TBL] [Abstract][Full Text] [Related]
9. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease. Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377 [TBL] [Abstract][Full Text] [Related]
10. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Volkow ND; Fowler JS; Wang GJ; Ding YS; Gatley SJ Eur Neuropsychopharmacol; 2002 Dec; 12(6):557-66. PubMed ID: 12468018 [TBL] [Abstract][Full Text] [Related]
11. PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter. Helfenbein J; Sandell J; Halldin C; Chalon S; Emond P; Okubo Y; Chou YH; Frangin Y; Douziech L; Gareau L; Swahn CG; Besnard JC; Farde L; Guilloteau D Nucl Med Biol; 1999 Jul; 26(5):491-9. PubMed ID: 10473187 [TBL] [Abstract][Full Text] [Related]
12. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. Tissingh G; Bergmans P; Winogrodzka A; Stoof JC; Wolters EC; Booij J; Van Royen EA J Nucl Med; 1997 Aug; 38(8):1271-2. PubMed ID: 9255164 [No Abstract] [Full Text] [Related]
13. Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. Villemagne VL; Rothman RB; Yokoi F; Rice KC; Matecka D; Dannals RF; Wong DF Synapse; 1999 Apr; 32(1):44-50. PubMed ID: 10188637 [TBL] [Abstract][Full Text] [Related]
14. [18F]CFT ([18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: biodistribution in rats. Haaparanta M; Bergman J; Laakso A; Hietala J; Solin O Synapse; 1996 Aug; 23(4):321-7. PubMed ID: 8855517 [TBL] [Abstract][Full Text] [Related]
15. In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner. Hume SP; Brown DJ; Ashworth S; Hirani E; Luthra SK; Lammertsma AA J Neurosci Methods; 1997 Sep; 76(1):45-51. PubMed ID: 9334938 [TBL] [Abstract][Full Text] [Related]
16. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Logan J; Ding YS; Hitzemann R; Pappas N Am J Psychiatry; 1998 Oct; 155(10):1325-31. PubMed ID: 9766762 [TBL] [Abstract][Full Text] [Related]
17. Specificity and ion dependence of binding of GBR analogs. Corera AT; Do Régo JC; Bonnet JJ Methods Enzymol; 1998; 296():203-19. PubMed ID: 9779450 [No Abstract] [Full Text] [Related]
18. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363 [TBL] [Abstract][Full Text] [Related]
19. Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine. Gatley SJ; Volkow ND; Gifford AN; Ding YS; Logan J; Wang GJ Biochem Pharmacol; 1997 Jan; 53(1):43-52. PubMed ID: 8960062 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two pet radioligands for imaging extrastriatal dopamine transporters in human brain. Wang GJ; Volkow ND; Fowler JS; Ding YS; Logan J; Gatley SJ; MacGregor RR; Wolf AP Life Sci; 1995; 57(14):PL187-91. PubMed ID: 7564877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]